Oxolife is a small-sized clinical-stage biotech company, founded in 2013 by Ignasi Canals and Agnès Arbat, focus and committed to female fertility improvement.
A solid project
It is estimated that infertility affects 75.8 million women worldwide. Each year, more than 3 million assisted reproduction procedures are performed, including in vitro fertilisation (IVF). Despite the treatments that exist to induce ovulation and modern techniques to mature and fertilise oocytes, more than half of all ART cycles end in disappointment due to Implantation failure or early pregnancy loss, the main causes of failure in female fertility treatments. These remain unsolved problems in reproductive medicine.
There is no pharmacological intervention in the market that enhances the implantation process through a direct effect on the endometrium. Oxolife’s innovation is a first-in-class oral drug for the treatment of infertile women, named OXO-001, that increases embryo implantation success and pregnancy rates.
Oxolife’s mission is to bring to market the first treatment that improves embryo implantation.
Our vision is to improve women’s fertility worldwide, simplifying the process that infertile women and couples go through. Also, give the scientific community the first implantation treatment available and improve understanding of the process of implantation.
We are guided by values of excellence, rigor, perseverance, determination, honesty, and the empowerment of people.